Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.58 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229953 | 0.84 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL671643 | 0.84 | LPAR3 (0.72) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL673141 | 0.84 | LPAR3 (0.72) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL672041 | 0.84 | LPAR3 (0.72) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL674769 | 0.84 | LPAR3 (0.72) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL674982 | 0.84 | LPAR3 (0.72) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL671712 | 0.84 | LPAR3 (0.72) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL9437033 | 0.82 | LPAR3 (0.75) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL22974810 | 0.82 | LPAR3 (0.75) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL21437002 | 0.82 | LPAR3 (0.75) | LPAR3LPAR2LPAR1LPAR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267980-A1 | CURING ACCELERATOR FOR DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN, DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN COMPOSITION, AND DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN CURED PRODUCT | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090118442-A1 | CURING ACCELERATOR FOR DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN, DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN COMPOSITION, AND DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN CURED PRODUCT | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267980-A1 | CURING ACCELERATOR FOR DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN, DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN COMPOSITION, AND DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN CURED PRODUCT | ELL, RAD54L, RPP30 | LPAR3 2209/4885LPAR2 2706/4885LPAR1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.